These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 23712329)

  • 1. CYP2D6 polymorphisms influence tamoxifen treatment outcomes in breast cancer patients: a meta-analysis.
    Zeng Z; Liu Y; Liu Z; You J; Chen Z; Wang J; Peng Q; Xie L; Li R; Li S; Qin X
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):287-303. PubMed ID: 23712329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen.
    Schroth W; Goetz MP; Hamann U; Fasching PA; Schmidt M; Winter S; Fritz P; Simon W; Suman VJ; Ames MM; Safgren SL; Kuffel MJ; Ulmer HU; Boländer J; Strick R; Beckmann MW; Koelbl H; Weinshilboum RM; Ingle JN; Eichelbaum M; Schwab M; Brauch H
    JAMA; 2009 Oct; 302(13):1429-36. PubMed ID: 19809024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis.
    Lum DW; Perel P; Hingorani AD; Holmes MV
    PLoS One; 2013; 8(10):e76648. PubMed ID: 24098545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial.
    Regan MM; Leyland-Jones B; Bouzyk M; Pagani O; Tang W; Kammler R; Dell'orto P; Biasi MO; Thürlimann B; Lyng MB; Ditzel HJ; Neven P; Debled M; Maibach R; Price KN; Gelber RD; Coates AS; Goldhirsch A; Rae JM; Viale G;
    J Natl Cancer Inst; 2012 Mar; 104(6):441-51. PubMed ID: 22395644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand.
    Sukasem C; Sirachainan E; Chamnanphon M; Pechatanan K; Sirisinha T; Ativitavas T; Panvichian R; Ratanatharathorn V; Trachu N; Chantratita W
    Asian Pac J Cancer Prev; 2012; 13(9):4549-53. PubMed ID: 23167378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.
    Fleeman N; Martin Saborido C; Payne K; Boland A; Dickson R; Dundar Y; Fernández Santander A; Howell S; Newman W; Oyee J; Walley T
    Health Technol Assess; 2011 Sep; 15(33):1-102. PubMed ID: 21906462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 2D6 and outcomes of adjuvant tamoxifen therapy: results of a meta-analysis.
    Seruga B; Amir E
    Breast Cancer Res Treat; 2010 Aug; 122(3):609-17. PubMed ID: 20454926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy.
    Damodaran SE; Pradhan SC; Umamaheswaran G; Kadambari D; Reddy KS; Adithan C
    Cancer Chemother Pharmacol; 2012 Jul; 70(1):75-81. PubMed ID: 22623212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.
    Hertz DL; Kidwell KM; Hilsenbeck SG; Oesterreich S; Osborne CK; Philips S; Chenault C; Hartmaier RJ; Skaar TC; Sikora MJ; Rae JM
    Breast Cancer Res Treat; 2017 Nov; 166(1):277-287. PubMed ID: 28730340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.
    Karle J; Bolbrinker J; Vogl S; Kreutz R; Denkert C; Eucker J; Wischnewsky M; Possinger K; Regierer AC
    Breast Cancer Res Treat; 2013 Jun; 139(2):553-60. PubMed ID: 23686417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Simulation Study to Compare the Treatment Effect of Tamoxifen by CYP2D6 Genotypes and Third-Generation Aromatase Inhibitors.
    Park GC; Jung JA; Bae KS; Lim HS
    J Clin Pharmacol; 2017 Sep; 57(9):1088-1096. PubMed ID: 28369967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
    Rae JM; Drury S; Hayes DF; Stearns V; Thibert JN; Haynes BP; Salter J; Sestak I; Cuzick J; Dowsett M;
    J Natl Cancer Inst; 2012 Mar; 104(6):452-60. PubMed ID: 22395643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.
    Abraham JE; Maranian MJ; Driver KE; Platte R; Kalmyrzaev B; Baynes C; Luccarini C; Shah M; Ingle S; Greenberg D; Earl HM; Dunning AM; Pharoah PD; Caldas C
    Breast Cancer Res; 2010; 12(4):R64. PubMed ID: 20731819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
    Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
    Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.
    Markkula A; Hjertberg M; Rose C; Ingvar C; Jernström H
    Acta Oncol; 2014 Feb; 53(2):195-200. PubMed ID: 24125101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
    Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
    Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of CYP2D6*10 polymorphism on tamoxifen pharmacokinetics in patients with breast cancer in Asia: a meta-analysis.
    Bai Y; Wu HW; Zhang YH
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):71-79. PubMed ID: 30357449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tailoring adjuvant endocrine therapy for postmenopausal breast cancer: a CYP2D6 multiple-genotype-based modeling analysis and validation.
    Yu KD; Huang AJ; Shao ZM
    PLoS One; 2010 Dec; 5(12):e15649. PubMed ID: 21187922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment.
    Xu Y; Sun Y; Yao L; Shi L; Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; He L; Li P; Xie Y
    Ann Oncol; 2008 Aug; 19(8):1423-1429. PubMed ID: 18407954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CYP2D6 Genetic Polymorphisms and Phenotypes in Different Ethnicities of Malaysian Breast Cancer Patients.
    Chin FW; Chan SC; Abdul Rahman S; Noor Akmal S; Rosli R
    Breast J; 2016; 22(1):54-62. PubMed ID: 26510986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.